Several other institutional investors have also bought and sold shares of the company. Donaldson Capital Management LLC boosted its position in shares of AbbVie by 2.1% in the third quarter. Donaldson Capital Management LLC now owns 436,260 shares of the company’s stock worth $27,515,000 after buying an additional 9,040 shares in the last quarter. Arete Wealth Advisors LLC purchased a new position in shares of AbbVie during the third quarter worth about $292,000. HighTower Advisors LLC boosted its position in shares of AbbVie by 2.8% in the third quarter. HighTower Advisors LLC now owns 644,371 shares of the company’s stock worth $40,635,000 after buying an additional 17,479 shares in the last quarter. Birch Hill Investment Advisors LLC boosted its position in shares of AbbVie by 1.7% in the third quarter. Birch Hill Investment Advisors LLC now owns 29,614 shares of the company’s stock worth $1,868,000 after buying an additional 502 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of AbbVie by 37.7% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 418,330 shares of the company’s stock worth $26,384,000 after buying an additional 114,628 shares in the last quarter. Hedge funds and other institutional investors own 67.25% of the company’s stock.
Two Sigma Advisers LP raised its position in AbbVie Inc. (NYSE:ABBV) by 44.3% during the third quarter, according to its most recent filing with the SEC. The firm owned 2,581,749 shares of the company’s stock after buying an additional 793,209 shares during the period. AbbVie makes up about 0.7% of Two Sigma Advisers LP’s investment portfolio, making the stock its 22nd largest position. Two Sigma Advisers LP owned approximately 0.16% of AbbVie worth $162,831,000 at the end of the most recent reporting period.
Shares of AbbVie Inc. (NYSE:ABBV) traded up 0.53% on Thursday, reaching $60.84. The company’s stock had a trading volume of 4,324,649 shares. The company’s 50-day moving average is $61.72 and its 200 day moving average is $62.56. The company has a market capitalization of $98.87 billion, a price-to-earnings ratio of 16.76 and a beta of 1.57. AbbVie Inc. has a 12-month low of $51.60 and a 12-month high of $68.12.
AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Friday, January 27th. The company reported $1.20 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.20. The firm had revenue of $6.78 billion for the quarter, compared to the consensus estimate of $6.92 billion. AbbVie had a return on equity of 141.55% and a net margin of 23.22%. The company’s quarterly revenue was up 6.0% on a year-over-year basis. During the same period in the prior year, the company posted $1.13 earnings per share. Equities analysts anticipate that AbbVie Inc. will post $5.48 earnings per share for the current fiscal year.
A number of equities research analysts recently commented on the company. Vetr lowered AbbVie from a “strong-buy” rating to a “buy” rating and set a $67.88 price target for the company. in a research report on Tuesday, January 31st. Leerink Swann assumed coverage on AbbVie in a research report on Tuesday, October 18th. They issued a “market perform” rating and a $70.00 price target for the company. Citigroup Inc lowered AbbVie from a “buy” rating to a “neutral” rating and set a $60.00 price target for the company. in a research report on Monday, November 28th. Finally, Credit Suisse Group lowered AbbVie from an “outperform” rating to a “neutral” rating and lowered their price target for the company from $70.00 to $60.00 in a research report on Monday, October 31st. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. AbbVie presently has an average rating of “Hold” and a consensus price target of $70.17.
In other news, CFO William J. Chase sold 6,600 shares of the company’s stock in a transaction on Friday, December 2nd. The stock was sold at an average price of $59.19, for a total transaction of $390,654.00. Following the transaction, the chief financial officer now directly owns 178,970 shares of the company’s stock, valued at $10,593,234.30. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 0.11% of the company’s stock.
AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company operates in pharmaceutical products segment. Its products are focused on treating conditions, such as chronic autoimmune diseases, in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, as well as other serious health conditions.
Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV).